CIK 0001637715 · <br>Emerging growth company
OnKure Therapeutics, Inc.
Sign in to watch- Ticker
- OKUR
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 472309515
- Phone
- (720) 307-2892
- Business address
- 6707 WINCHESTER CIRCLE, SUITE 400, BOULDER, CO, 80301
- Former names
- Reneo Pharmaceuticals, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,157
- in 2 filings
Net −$1,157. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 35 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-08-28 | Hall Ashley Chief Development Officer | Option exercise | +15,625 | $1.80 | $28K | 55,225 |
| 2023-08-28 | Hall Ashley Chief Development Officer | Sale | −15,625 | $6.28 | $98K | 39,600 |
| 2023-08-28 | Hall Ashley Chief Development Officer | Option exercise · Stock option (right to buy) | −15,625 | 109,375 | ||
| 2023-07-26 | GREY MICHAEL G Executive Chairman | Gift | −50,000 | 0 | ||
| 2023-06-23 | Novo Holdings A/S 10% owner | Sale | −100,000 | $7.10 | $710K | 3,330,337 |
| 2023-06-06 | Mathers Edward T Director | Grant or award · Stock Option (right to buy) | −17,500 | 17,500 | ||
| 2023-06-06 | Blunt Roshawn A. Director | Grant or award · Stock Option (right to buy) | +14,815 | 14,815 | ||
| 2023-06-06 | GREY MICHAEL G Executive Chairman | Grant or award · Stock Option (right to buy) | +17,500 | 17,500 | ||
| 2023-06-06 | Hoelscher Paul W. Director | Grant or award · Stock Option (right to buy) | +17,500 | 17,500 | ||
| 2023-06-06 | Muralidhar Bali Director | Grant or award · Stock Option (right to buy) | +17,500 | 17,500 | ||
| 2023-06-06 | O'Donnell Niall Director | Grant or award · Stock Option (right to buy) | +17,500 | 17,500 | ||
| 2023-06-06 | Seltzer Stacey Denenberg Director | Grant or award · Stock Option (right to buy) | +17,500 | 17,500 | ||
| 2023-06-06 | Dube Eric M Director | Grant or award · Stock Option (right to buy) | +17,500 | 17,500 | ||
| 2023-05-08 | O'Donnell Niall Director | Purchase | +125,000 | $8.00 | $1.0M | 2,188,713 |
| 2022-12-09 | Lam Jennifer VP of Finance & Administration | Grant or award · Stock option (right to buy) | +90,000 | 90,000 | ||
| 2022-12-09 | Hall Ashley Chief Development Officer | Grant or award · Stock option (right to buy) | +125,000 | 125,000 | ||
| 2022-12-09 | FLESHER GREGORY J. President and CEO | Grant or award · Stock option (right to buy) | +300,000 | 300,000 | ||
| 2022-12-09 | Dorenbaum Alejandro Chief Medical Officer | Grant or award · Stock option (right to buy) | +125,000 | 125,000 | ||
| 2022-12-09 | Cruse Michael Chief Operating Officer | Grant or award · Stock option (right to buy) | +125,000 | 125,000 | ||
| 2022-09-01 | Cruse Michael Chief Operating Officer | Purchase | +7,500 | $3.39 | $25K | 13,697 |
Page 7 of 8 · 154 trades